Phenomix Sciences

Executive Summary

Phenomix Sciences is a precision medicine company leveraging artificial intelligence to integrate genetic, clinical, and biomarker data for obesity management. Its flagship product, the MyPhenome Test, aims to stratify patients by obesity subtypes and predict the most effective treatment pathways, enabling personalized interventions that improve outcomes and reduce costs. Founded in 2018 and based in Minneapolis, the company targets a significant unmet need in obesity care, where one-size-fits-all approaches often fail. By combining advanced analytics with a deep understanding of obesity pathophysiology, Phenomix has the potential to disrupt the $100B+ obesity treatment market, shifting from trial-and-error prescribing to targeted therapy selection. The platform's ability to identify responders to specific drugs (e.g., GLP-1 agonists, surgery) could drive adoption among payers and providers seeking cost-effective solutions. While still early-stage, the company's focus on a validated commercial test positions it for growth in a rapidly expanding market.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch and reimbursement coverage for MyPhenome Test70% success
• Q2 2026Publication of clinical validation study demonstrating improved weight loss outcomes with test-guided treatment60% success
• Q4 2026Strategic partnership with a major health system or obesity clinic network for pilot deployment50% success